Shanghai, China, Aug 31,2023./ OBiO Technology (Shanghai) Corp., Ltd. (”OBiO” or the “Company”, Stock code: SH688238) today announced that it entered into a strategic cooperation agreement (the "Agreement") with today announced that it entered into a strategic cooperation agreement with Shanghai Tofflon Science and Technology Co.Ltd.(Short for “Tofflon”, Stock code:SZ300171).

OBiO Technology (Shanghai) Corp., Ltd ('OBiO', 688238. SH) is a biotechnology company focusing on the cell and gene therapy field. Recently announced that the U.S. Food and Drug Administration (FDA) has successfully obtained the GMP plasmid DNA Drug Master File (DMF) filing.

On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE.

On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. ("OBiO" or "the Company"), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world.

OBiO Techonoly congratulates Immvira that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial in China.